Stay Ahead of Wall Street. Find out what is happening to MyoKardia, Inc. (NASDAQ:MYOK) stock today? Its price is nose-diving -2.01 points, trading at $45.76 levels, and is down -4.21% from its previous close of $47.77. The shares seem to have an active trading volume day with a reported 121206 contracts so far this session. MYOK shares had a relatively better volume day versus average trading capacity of 507.81 thousand shares, but with a 43.54 million float and a 4.48% run over a week, it’s definitely worth keeping an eye on. The one year price forecast for MYOK stock indicates that the average analyst price target is $78.38 per share. This means the stock has a potential increase of 71.28% from where the MYOK share price has been trading recently which is between $47.51 and $49.23. There are some brokerage firms that offer lower targets than the average, with one of them, even setting their price target at $65.
The shorts are climbing into MyoKardia, Inc. (MYOK) stock. The latest set of short interest data was released on 15 May 2019, and the numbers show a rise in short interest in MYOK shares. While short interest still represents only 8.63% of MYOK’s float, the number of shares shorted have risen by 355231. The number of shares shorted advanced to 3756341 shares, up from 3401110 shares during the preceding fortnight. With average daily trading volumes at 537996 shares, days to cover decreased to about 9.403696 days. The most recent news story about the stock that appeared in Yahoo Finance‘s news section was titled “MyoKardia Presents Results from Phase 1a Clinical Trial of MYK-491 at the European Society of Cardiology Heart Failure Congress in Athens, Greece” and dated May 28, 2019.
During the recent trading session for MyoKardia, Inc. (NASDAQ:MYOK), the company witnessed their stock drop by $-1.82 over a week and tumble down $-0.12 from the price 20 days ago. When compared to their established 52-week high of $67.79, the high they recorded in their recent session happens to be lower. Their established 52-week high was attained by the company on 10/01/18. The recent low of $39.01 stood for a -32.49% since 02/13/19, a data which is good for most investors who are looking to take advantage of the stock’s recent rise. A beta of 2.1 is also allocated to the stock. Since the beta is greater than one, it implies that the stock is more volatile than the market, a data that traders are keeping close attention to.
Looking at the current readings for MyoKardia, Inc., the two-week RSI stands at 41.83. This figure suggests that MYOK stock, for now, is neutral, meaning that the shares are stable in terms of price movement. The stochastic readings, on the other hand, based on the current MYOK readings is similarly very revealing as it has a stochastic reading of 31.28% at this stage. This figure means that MYOK share price today is being neutral.
Technical chart claims that MyoKardia, Inc. (MYOK) would settle between $48.83/share to $49.89/share level. However, if the stock price goes below the $47.11 mark, then the market for MyoKardia, Inc. becomes much weaker. If that happens, the stock price might even plunge as low as $46.45 for its downside target. The stock is currently in the green zone of MACD, with the indicator reading 0.09. Traders are always alerted for the move of a stock above or below the zero line due to the fact that the reading is an indicator of the position of the short-term average relative to the long-term average. If the MACD is above the zero line, then the short-term average relative is above that of the long-term average, thus implying an upward momentum. Vice versa is the case if the MACD is below the zero line.
Analysts at Cantor Fitzgerald, assumed coverage of MYOK assigning Overweight rating, according to their opinion released on October 01. Citigroup, analysts launched coverage of MyoKardia, Inc. (NASDAQ:MYOK) stock with a Buy recommendation, according to their flash note issued to investors on September 28. Analysts at Morgan Stanley, made their first call for the equity with a Overweight recommendation, according to a research note that dated back to September 10.
MYOK equity has an average rating of 1.6, with the figure leaning towards a bullish end. 10 analysts who tracked the company were contacted by Reuters. Amongst them, 0 rated the stock as a hold while the remaining 10 were split even though not equally. Some analysts rate the stock as a buy or a strong buy while no rated it as a sell. 10 analysts rated MyoKardia, Inc. (NASDAQ:MYOK) as a buy or a strong buy while not a single analyst advised that investors should desist from purchasing the stock or sell them if they already own the company’s stock.
Moving on, MYOK stock price is currently trading at 0X forward 12-month Consensus EPS estimates, and its P/S ratio is 33.1 while for the average stock in the same group, the multiple is 49.5.
MyoKardia, Inc. (MYOK)’s current-quarter revenues are projected to climb by nearly 88.25% to hit $12.5 million, based on current Zacks Consensus Estimate. The firm’s full-year revenues are expected to expand by over -26.5% from $33.56 million to a noteworthy $24.67 million. At the other end of the current quarter income statement, MyoKardia, Inc. is expected to see its adjusted earnings surge by roughly -61.22% to hit $-0.79 per share. For the fiscal year, MYOK’s earnings are projected to climb by roughly -98.86% to hit $-3.5 per share.